1
|
Soleimani S, Alizadeh Shargh S, Keramatinia A, Mehrvar N, Mansouri N, Doosti A, Mortazavi-Tabatabaei SA, Hashemi M, Movafagh A. Detection of gene expression in sentinel lymph node of primary breast cancer patients. Cell Mol Biol (Noisy-le-grand) 2018; 64:118-121. [PMID: 29729704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2017] [Revised: 10/06/2017] [Accepted: 10/06/2017] [Indexed: 06/08/2023]
Abstract
Sentinel lymph node (SLN) micrometstasis detection improves outcome for breast cancer follow up procedure. The aim of the present study was to identify gene profiles that accurately predicted the outcome of breast cancer patients. Fifty tumor sample from breast cancer patients were analyzed for the expression of 3 genes using quantitative-PCR. Also clinical verification for recurrence to distant organs was performed. Three gene signature were confirmed based on tumor's stage, grade, ER status, using conditional logistic regression. Based on this findings, the negative reported lymph nodes for metastasis, had micro metastasis in significant values. There was a significant difference between normal and cancer samples in 3 gene expression marker and also there was meaningful relationship between three gene expression with tumor's grade, stage according to progression of tumor. A novel gene expression signature predictive of micro metastatic patients was evaluated. In this assessment, relationship between this gene with tumor's features that finding clear role for these genes with tumor's outcome, needs to be established.
Collapse
Affiliation(s)
- Shahrzad Soleimani
- Department of Molecular Genetics, Institute of Basic Science, Shahrekord Islamic Azad University, Iran
| | - Shohreh Alizadeh Shargh
- Medical Laboratory Science Department, Midwifery-Nursing Institute, Islamic Azad University of Chalous Branch, Chalous, Iran
| | - Aliasghar Keramatinia
- Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Narjes Mehrvar
- Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Neda Mansouri
- Department of Medical Genetics, Cancer Research Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Abbas Doosti
- Department of Molecular Genetics, Institute of Basic Science, Shahrekord Islamic Azad University, Iran
| | | | - Mehrdad Hashemi
- Department of Molecular Genetics, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran
| | - Abolfazl Movafagh
- Department of Medical Genetics, Cancer Research Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| |
Collapse
|
2
|
Li C, Zhang T. Human mammaglobin: A specific marker for breast cancer prognosis. J BUON 2016; 21:35-41. [PMID: 27061528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
PURPOSE In this study, we examined the expression of human mammaglobin (hMAM) mRNA and the protein levels in patients with breast cancer and their relationship with prognostic clinicopathological parameters. METHODS hMAM mRNA expression in leucocytes from peripheral blood samples from patients diagnosed with primary invasive breast cancer (IC), carcinoma in situ (CIS), or benign breast diseases was analyzed using RT-PCR. The hMAM protein levels and expression patterns in tissue from 3 patient groups were evaluated by immunohistochemical staining, and several non-breast neoplasms were selected as negative controls, undergoing the same examination. RESULTS The expression of hMAM mRNA was significantly higher in patients with IC or CIS compared to those with benign tumors (both<0.01). Immunohistochemical staining revealed similar results, where patients with IC or CIS had higher levels of hMAM protein (p<0.01 and p<0.01, respectively), while none of the negative controls expressed hMAM. Further analyses showed a strong correlation between hMAM protein/mRNA expression and clinicopathological factors, such as histological grade, clinical stage, and lymph node status, in patients with IC. CONCLUSION The hMAM mRNA and protein expression profiles validate the potential of hMAM as a specific marker for breast cancer diagnosis and target treatment delivery.
Collapse
Affiliation(s)
- Chuanying Li
- Department of Pathology, Shandong University School of Medicine, Shandong, 250012, P.R. China
| | | |
Collapse
|
3
|
Tiriveedhi V, Tucker N, Herndon J, Li L, Sturmoski M, Ellis M, Ma C, Naughton M, Lockhart AC, Gao F, Fleming T, Goedegebuure P, Mohanakumar T, Gillanders WE. Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancer. Clin Cancer Res 2015; 20:5964-75. [PMID: 25451106 DOI: 10.1158/1078-0432.ccr-14-0059] [Citation(s) in RCA: 59] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE Mammaglobin-A (MAM-A) is overexpressed in 40% to 80% of primary breast cancers. We initiated a phase I clinical trial of a MAM-A DNA vaccine to evaluate its safety and biologic efficacy. EXPERIMENTAL DESIGN Patients with breast cancer with stable metastatic disease were eligible for enrollment. Safety was monitored with clinical and laboratory assessments. The CD8 T-cell response was measured by ELISPOT, flow cytometry, and cytotoxicity assays. Progression-free survival (PFS) was described using the Kaplan-Meier product limit estimator. RESULTS Fourteen subjects have been treated with the MAM-A DNA vaccine and no significant adverse events have been observed. Eight of 14 subjects were HLA-A2(+), and the CD8 T-cell response to vaccination was studied in detail. Flow cytometry demonstrated a significant increase in the frequency of MAM-A-specific CD8 T cells after vaccination (0.9% ± 0.5% vs. 3.8% ± 1.2%; P < 0.001), and ELISPOT analysis demonstrated an increase in the number of MAM-A-specific IFNγ-secreting T cells (41 ± 32 vs. 215 ± 67 spm; P < 0.001). Although this study was not powered to evaluate progression-free survival (PFS), preliminary evidence suggests that subjects treated with the MAM-A DNA vaccine had improved PFS compared with subjects who met all eligibility criteria, were enrolled in the trial, but were not vaccinated because of HLA phenotype. CONCLUSION The MAM-A DNA vaccine is safe, capable of eliciting MAM-A-specific CD8 T-cell responses, and preliminary evidence suggests improved PFS. Additional studies are required to define the potential of the MAM-A DNA vaccine for breast cancer prevention and/or therapy.
Collapse
Affiliation(s)
- Venkataswarup Tiriveedhi
- Department of Surgery, Washington University School of Medicine, St. Louis, Missouri. Department of Biological Sciences, Tennessee State University, Nashville, Tennessee
| | - Natalia Tucker
- Department of Surgery, Washington University School of Medicine, St. Louis, Missouri
| | - John Herndon
- Department of Surgery, Washington University School of Medicine, St. Louis, Missouri
| | - Lijin Li
- Department of Surgery, Washington University School of Medicine, St. Louis, Missouri
| | - Mark Sturmoski
- Department of Surgery, Washington University School of Medicine, St. Louis, Missouri
| | - Matthew Ellis
- Department of Medicine, Washington University School of Medicine, St. Louis, Missouri. The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, Missouri
| | - Cynthia Ma
- Department of Medicine, Washington University School of Medicine, St. Louis, Missouri. The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, Missouri
| | - Michael Naughton
- Department of Medicine, Washington University School of Medicine, St. Louis, Missouri. The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, Missouri
| | - A Craig Lockhart
- Department of Medicine, Washington University School of Medicine, St. Louis, Missouri. The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, Missouri
| | - Feng Gao
- The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, Missouri. Division of Biostatistics, Washington University School of Medicine, St. Louis, Missouri
| | - Timothy Fleming
- Department of Surgery, Washington University School of Medicine, St. Louis, Missouri. The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, Missouri
| | - Peter Goedegebuure
- Department of Surgery, Washington University School of Medicine, St. Louis, Missouri. The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, Missouri
| | - Thalachallour Mohanakumar
- Department of Surgery, Washington University School of Medicine, St. Louis, Missouri. The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, Missouri. Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri
| | - William E Gillanders
- Department of Surgery, Washington University School of Medicine, St. Louis, Missouri. The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, Missouri.
| |
Collapse
|
4
|
Skondra M, Gkioka E, Kostakis ID, Pissimissis N, Lembessis P, Pectasides D, Koutsilieris M. Detection of circulating tumor cells in breast cancer patients using multiplex reverse transcription-polymerase chain reaction and specific primers for MGB, PTHRP and KRT19 correlation with clinicopathological features. Anticancer Res 2014; 34:6691-6699. [PMID: 25368276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
AIM The aim of this study was to correlate the clinicopathological features of breast cancer patients with the positive detection of parathyroid hormone-related protein (PTHRP), cytokeratin protein 19 (KRT19) and mammaglobin (MGB) using a multiplex reverse transcription polymerase chain reaction (RT-PCR) assay developed to detect circulating tumor cells (CTCs) in peripheral blood of patients with breast cancer. PATIENTS AND METHODS Peripheral blood samples were collected from 54 breast cancer patients and 20 healthy blood donors. Subsequently, the samples were processed for RNA extraction and analyzed for the expression of PTHRP, KRT19 and MGB using specific primers and multiplex RT-PCR. RESULTS The positive detection rates in breast cancer patients for PTHRP, KRT19 and MGB were 68.5%, 63% and 22.2% and for healthy donors 10%, 0% and 10%, respectively. The statistical analysis revealed that PTHRP- and KRT19-positive detections correlated with the diagnosis of breast cancer while the combined positive detections of PTHRP-plus-KRT19 correlated with the presence of distant metastasis, especially with bone metastasis. Moreover, positive detections of KRT19 correlated with high proliferation rate of breast cancer tumors. MGB-positive detections did not add any diagnostic advantage in such analysis. CONCLUSION Multiplex-PCR based detection of CTCs using PTHRP and KRT19 primers can provide useful information for the disease.
Collapse
MESH Headings
- Adult
- Aged
- Biomarkers, Tumor
- Bone Neoplasms/blood
- Bone Neoplasms/genetics
- Bone Neoplasms/secondary
- Breast Neoplasms/blood
- Breast Neoplasms/genetics
- Breast Neoplasms/pathology
- Carcinoma, Ductal, Breast/blood
- Carcinoma, Ductal, Breast/genetics
- Carcinoma, Ductal, Breast/secondary
- Carcinoma, Lobular/blood
- Carcinoma, Lobular/genetics
- Carcinoma, Lobular/secondary
- Case-Control Studies
- Female
- Follow-Up Studies
- Humans
- Keratin-19/genetics
- Lymphatic Metastasis
- Mammaglobin A/genetics
- Middle Aged
- Neoplasm Grading
- Neoplasm Staging
- Neoplastic Cells, Circulating/pathology
- Prognosis
- RNA, Messenger/blood
- RNA, Messenger/genetics
- RNA, Neoplasm/blood
- RNA, Neoplasm/genetics
- Receptor, Parathyroid Hormone, Type 1/genetics
- Reverse Transcriptase Polymerase Chain Reaction
Collapse
Affiliation(s)
- Maria Skondra
- Department of Experimental Physiology, National and Kapodistrian University of Athens, Medical School, Athens, Greece Second Department of Internal Medicine University of Athens, Hippokratio Hospital, Athens, Greece
| | - Eliona Gkioka
- Department of Experimental Physiology, National and Kapodistrian University of Athens, Medical School, Athens, Greece
| | - Ioannis D Kostakis
- Second Department of Propedeutic Surgery National and Kapodistrian University of Athens, Medical School, Athens, Greece
| | - Nikolaos Pissimissis
- Department of Experimental Physiology, National and Kapodistrian University of Athens, Medical School, Athens, Greece
| | - Panagiotis Lembessis
- Department of Experimental Physiology, National and Kapodistrian University of Athens, Medical School, Athens, Greece
| | - Dimitrios Pectasides
- Second Department of Internal Medicine University of Athens, Hippokratio Hospital, Athens, Greece
| | - Michael Koutsilieris
- Department of Experimental Physiology, National and Kapodistrian University of Athens, Medical School, Athens, Greece
| |
Collapse
|
5
|
Ghersevich S, Ceballos MP. Mammaglobin A: review and clinical utility. Adv Clin Chem 2014; 64:241-268. [PMID: 24938021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Mammaglobin A is a protein that belongs to the secretoglobin superfamily. It has highly specific expression in cells from most breast cancers and may be used to detect circulating or disseminated tumor cells. In addition, mammaglobin A is currently under inves tigation as a potential therapeutic target for immune therapies that target breast cancer. The present review will highlight our current understanding of mammaglobin A at the genetic and protein level and its potential clinical applications. Characteristics of breast cancer and methods used to isolate and detect circulating tumor cells will also be presented.
Collapse
|
6
|
Tao XA, Xiao JY, Zeng Q, Cheng B. [Expression of secretoglobin family 2A member 2 in oral lichen planus lesions]. Zhonghua Kou Qiang Yi Xue Za Zhi 2013; 48:606-609. [PMID: 24438568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
OBJECTIVE To examine the expression of secretoglobin family 2A member 2 (SCGB2A2) (mammaglobin A, MGB1) in oral lichen planus (OLP) lesions. METHODS Sixteen OLP patients and 10 healthy controls were included in this study. The real time reverse transcription-PCR (RT-PCR), Western blotting and immunohistochemistry (IHC) were used to determine the mRNA and protein of SCGB2A2. RESULTS Compared with healthy controls (0.48 ± 0.09), the expression of SCGB2A2 protein in OLP lesions significantly increased (1.02 ± 0.11) (P < 0.05).However, the mRNA level of SCGB2A2 in lesions was significantly lower than that in controls (P < 0.05). CONCLUSIONS These results suggest that SCGB2A2 may be involved in pathogenesis of OLP.
Collapse
Affiliation(s)
- Xiao-an Tao
- Department of Oral Medicine,Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-sen University & Guangdong Provincial Key Laboratory of Stomatology, Guangzhou 510055, China
| | | | | | | |
Collapse
|
7
|
Andergassen U, Hofmann S, Kölbl AC, Schindlbeck C, Neugebauer J, Hutter S, Engelstädter V, Ilmer M, Friese K, Jeschke U. Detection of tumor cell-specific mRNA in the peripheral blood of patients with breast cancer—evaluation of several markers with real-time reverse transcription-PCR. Int J Mol Sci 2013; 14:1093-104. [PMID: 23299436 PMCID: PMC3565309 DOI: 10.3390/ijms14011093] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2012] [Revised: 12/03/2012] [Accepted: 12/31/2012] [Indexed: 01/05/2023] Open
Abstract
It is widely known that cells from epithelial tumors, e.g., breast cancer, detach from their primary tissue and enter blood circulation. We show that the presence of circulating tumor cells (CTCs) in samples of patients with primary and metastatic breast cancer can be detected with an array of selected tumor-marker-genes by reverse transcription real-time PCR. The focus of the presented work is on detecting differences in gene expression between healthy individuals and adjuvant and metastatic breast cancer patients, not an accurate quantification of these differences. Therefore, total RNA was isolated from blood samples of healthy donors and patients with primary or metastatic breast cancer after enrichment of mononuclear cells by density gradient centrifugation. After reverse transcription real-time PCR was carried out with a set of marker genes (BCSP, CK8, Her2, MGL, CK18, CK19). B2M and GAPDH were used as reference genes. Blood samples from patients with metastatic disease revealed increased cytokine gene levels in comparison to normal blood samples. Detection of a single gene was not sufficient to detect CTCs by reverse transcription real-time PCR. Markers used here were selected based on a recent study detecting cancer cells on different protein levels. The combination of such a marker array leads to higher and more specific discovery rates, predominantly in metastatic patients. Identification of CTCs by PCR methods may lead to better diagnosis and prognosis and could help to choose an adequate therapy.
Collapse
Affiliation(s)
- Ulrich Andergassen
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe Ludwig-Maximilians-Universitaet Muenchen, Campus Innenstadt, Maistraße 11, 80337 Munich, Germany; E-Mails: (U.A.); (S.H.); (A.C.K.); (J.N.); (S.H.); (V.E.); (K.F.)
| | - Simone Hofmann
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe Ludwig-Maximilians-Universitaet Muenchen, Campus Innenstadt, Maistraße 11, 80337 Munich, Germany; E-Mails: (U.A.); (S.H.); (A.C.K.); (J.N.); (S.H.); (V.E.); (K.F.)
| | - Alexandra C. Kölbl
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe Ludwig-Maximilians-Universitaet Muenchen, Campus Innenstadt, Maistraße 11, 80337 Munich, Germany; E-Mails: (U.A.); (S.H.); (A.C.K.); (J.N.); (S.H.); (V.E.); (K.F.)
| | - Christian Schindlbeck
- Frauenklinik, Klinikum Traunstein, Cuno-Niggl-Straße 3, 83278 Traunstein, Germany; E-Mail:
| | - Julia Neugebauer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe Ludwig-Maximilians-Universitaet Muenchen, Campus Innenstadt, Maistraße 11, 80337 Munich, Germany; E-Mails: (U.A.); (S.H.); (A.C.K.); (J.N.); (S.H.); (V.E.); (K.F.)
| | - Stefan Hutter
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe Ludwig-Maximilians-Universitaet Muenchen, Campus Innenstadt, Maistraße 11, 80337 Munich, Germany; E-Mails: (U.A.); (S.H.); (A.C.K.); (J.N.); (S.H.); (V.E.); (K.F.)
| | - Verena Engelstädter
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe Ludwig-Maximilians-Universitaet Muenchen, Campus Innenstadt, Maistraße 11, 80337 Munich, Germany; E-Mails: (U.A.); (S.H.); (A.C.K.); (J.N.); (S.H.); (V.E.); (K.F.)
| | - Matthias Ilmer
- Department of Molecular Pathology, University of Texas MD Anderson Cancer Center, 7435 Fannin Street, Houston, TX 77054, USA; E-Mail:
| | - Klaus Friese
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe Ludwig-Maximilians-Universitaet Muenchen, Campus Innenstadt, Maistraße 11, 80337 Munich, Germany; E-Mails: (U.A.); (S.H.); (A.C.K.); (J.N.); (S.H.); (V.E.); (K.F.)
| | - Udo Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe Ludwig-Maximilians-Universitaet Muenchen, Campus Innenstadt, Maistraße 11, 80337 Munich, Germany; E-Mails: (U.A.); (S.H.); (A.C.K.); (J.N.); (S.H.); (V.E.); (K.F.)
- Author to whom correspondence should be addressed; E-Mail: ; Tel.: +49-89-5160-4111; Fax: +49-89-5160-4715
| |
Collapse
|
8
|
Reinholz MM, Kitzmann KA, Tenner K, Hillman D, Dueck AC, Hobday TJ, Northfelt DW, Moreno-Aspitia A, Roy V, LaPlant B, Allred JB, Stella PJ, Lingle WL, Perez EA. Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437. Clin Cancer Res 2011; 17:7183-93. [PMID: 21976532 DOI: 10.1158/1078-0432.ccr-11-0981] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
PURPOSE To investigate the associations between baseline and posttreatment circulating tumor cell (CTC) gene expression and outcome of patients enrolled in four North Central Cancer Treatment Group metastatic breast cancer (MBC) trials in which specimens were shipped (at 4°C) from community-based sites to a reference laboratory (Mayo Clinic, Rochester, MN). EXPERIMENTAL DESIGN Blood was collected at treating sites from MBC patients before (baseline), during, and at the end of treatment with erlotinib + gemcitabine (N0234), sorafenib (N0336), irinotecan + cetuximab (N0436), or paclitaxel-poliglumex + capecitabine (N0437). CTCs from 10 mL of EDTA blood were enriched with CD45 depletion, 24 to 30 hours postblood collection. Reverse transcription/quantitative PCR was used to determine cytokeratin-19 (CK19) and mammaglobin (MGB1) mRNA levels in CTCs from up to 13 (N0234), 16 (N0336), 18 (N0436), and 39 (N0437) patients. The gene expressions were normalized to β(2)-microglobulin and calibrated to healthy blood using the 2(-ΔΔCq) algorithm; positivity was defined as 2 or more. RESULTS CK19+mRNA cells were detected in 56% to 75% and MGB1+mRNA cells in 23% to 38% of 86 patients at baseline. CK19+mRNA cells were detected in 30% to 67% and MGB1+mRNA cells in 14% to 64% of 110 postbaseline serial samples. The presence of baseline CK19+mRNA cells (P = 0.01) but not MGB1+mRNA cells (P = 0.14) was significantly associated with shorter overall survival. A decrease in MGB1+mRNA levels (baseline-week 8) seemed to be associated with clinical response (P = 0.05). CONCLUSIONS CTC gene expression analysis conducted by a reference laboratory is feasible when blood is collected from treating sites and processed 24 to 30 hours postcollection. The presence of baseline CK19+mRNA CTCs was associated with poor prognosis; a decrease in MGB1+mRNA CTCs may help predict response to therapy of MBC patients.
Collapse
Affiliation(s)
- Monica M Reinholz
- Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55906, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|